Li, Guangrui
Yamasaki, Ryo
Fang, Mei
Masaki, Katsuhisa
Ochi, Hirofumi
Matsushita, Takuya
Kira, Jun-ichi
Article History
Received: 19 May 2017
Accepted: 17 January 2018
First Online: 31 January 2018
Competing Interests
: R. Yamasaki has received honoraria from Biogen Japan and Japan Blood Products Organization; H. Ochi serves as a scientific advisory board member of Biogen Japan and has received honoraria from Bayer Healthcare, Novartis Pharma, Mitsubishi Tanabe Pharma Corporation, Nihon Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd.; T. Matsushita has received honoraria from Bayer Healthcare, Biogen Japan, Takeda Pharmaceutical Co. Ltd., and Mitsubishi Tanabe Pharma; J. Kira is a consultant for Biogen Japan and Medical Review, and has received honoraria from Bayer Healthcare, Mitsubishi Tanabe Pharma, Nobelpharma, Otsuka Pharmaceutical, Sanofi K.K., Chugai Pharmaceutical Co. Ltd., Teijin Pharma, Novartis Pharma, and Medical Review; the other authors declare no conflicts of interest.